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Abstract
Introduction: The mechanisms that mediate nicotine withdrawal are presently
unclear and age group differences in the neurochemical effects of withdrawal have been
largely unexplored. Previous studies in our laboratory demonstrated that adult rats display a
decrease in extracellular levels of dopamine in the nucleus accumbens (NAcc) during
nicotine withdrawal and this decrease is reduced in adolescent rats (Natividad et al., 2010).
The goal of this dissertation was to examine whether these age group differences in
dopamine during withdrawal are mediated via excitatory and inhibitory mechanisms that
modulate dopamine in the cell body region of the ventral tegmental area (VTA). Methods:
Adolescent and adult rats (n=7-14) were prepared with subcutaneous pumps that delivered an
equivalent dose of nicotine. On day 13 of nicotine exposure, the rats were implanted with
microdialysis probes into the NAcc and the ipsilateral VTA. Dialysates collected from the
NAcc were assayed for dopamine and the results were previously published (Natividad et al.,
2010). The data presented here reflect dialysates collected from the VTA of the same rats. On
day 14 of nicotine exposure, extracellular levels of glutamate and gamma-aminobutyric acid
(GABA) in the VTA were monitored following administration of escalating doses of the
nicotinic receptor antagonist mecamylamine to precipitate withdrawal. To examine whether
mecamylamine alone produced neurochemical changes, a group of drug-naïve adolescent and
adult rats (n=6 per group) received a sham surgery and were then monitored for extracellular
levels of dopamine in the NAcc following the same dose regimen of mecamylamine.
Results: Naïve rats of both age groups did not exhibit any alterations in NAcc dopamine
levels following mecamylamine administration, suggesting that our pharmacological tool to
precipitate withdrawal alone does not alter neurochemical measures. In adult rats, nicotine
withdrawal produced a decrease in VTA glutamate levels (44% maximal decrease) and an
vi

increase in GABA levels (38% increase), consistent with an overall inhibition of dopamine
cell activity. In contrast, adolescents did not exhibit significant changes in either VTA
glutamate or GABA levels during nicotine withdrawal. In order to examine the relationship
between NAcc dopamine and VTA amino acid transmission, regression analyses were
performed for each age group before and after withdrawal. Following mecamylamine,
decreases in dopamine were positively correlated with decreases in glutamate in adults,
whereas adolescents did not exhibit any significant correlation. The relationship between
dopamine and glutamate was significantly stronger in adult versus adolescent rats. Similarly,
decreases in dopamine were negatively correlated with increases in GABA in adults, whereas
adolescents did not exhibit any significant correlation. The relationship between dopamine
and GABA was also significantly stronger in adult versus adolescent rats. Discussion:
Overall, the results revealed that adults display a decrease in dopamine during nicotine
withdrawal. This effect appears to be related to a decrease in excitatory and an increase in
inhibitory mechanisms that modulate dopamine transmission in the cell body region of the
VTA. On the other hand, adolescents appear to be resistant to these neurochemical changes
that follow nicotine withdrawal. Specifically, adolescents do not exhibit deficits in VTA
glutamate and elevations in VTA GABA that contribute to the decreases in NAcc dopamine
during withdrawal in adults. Taken together, these results indicate that adolescents display
resistance to withdrawal-related neurochemical processes that inhibit mesolimbic dopamine
function in adults experiencing nicotine withdrawal. The findings provide a potential
mechanism involving VTA amino acid neurotransmission that may begin to explain age
group differences in nicotine withdrawal.
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Chapter 1: Introduction

I. Human Tobacco Use

Tobacco use is a major health and economic concern in the United States. Tobacco use
remains the leading cause of preventable death and disease in the United States. In 2010, an
estimated 70 million Americans reported daily use of tobacco products [National Survey on
Drug Use and Health (NSDUH), 2011]. The high rates of tobacco use are alarming given that
many chronic diseases are closely linked to tobacco use, including lung cancer, ischemic heart
disease and chronic obstructive pulmonary disease [Centers for Disease Control and Prevention
(CDC), 2008]. In fact, it is estimated that 443,000 Americans die every year from illnesses
associated with tobacco use. Moreover, for every one person who dies from a tobacco-related
disease, 20 others suffer from a major health issue related to their tobacco use (CDC, 2003).
Consequently, this poses a significant burden on the American economy, as medical treatment
for tobacco users is projected to cost $96 billion a year (CDC, 2008). Efforts to reduce tobacco
use are important, as many epidemiological studies demonstrate that tobacco-related mortality
and hospitalizations have decreased with the recent implementation of smoking ordinances
(CDC, 2009a, 2009b, and 2011).

Adolescent tobacco use is especially concerning. Tobacco use among adolescents is
pervasive. This is concerning because adolescents display a stronger propensity to experiment
with and then become addicted to tobacco. Adolescents are also more likely to become long-term
tobacco users if they initiate use during adolescence (Brook et al., 2008; Janson, 1999; Riggs et
1

al., 2007; Taioli and Wynder, 1991). In fact, 80% of tobacco use begins before the age of 18
(NSDUH, 2009). While there has been a slight decline in tobacco use in the United States, the
rates of smoking initiation remain high among adolescents (CDC, 2010). Every day,
approximately 3,800 young people in the United States try their first tobacco product, and of
these first-time users, 1,000 of them will go on to become daily users (NSDUH, 2011). Given
that tobacco use leads to deleterious health consequences, young people that smoke are at
heightened risk of developing tobacco-related diseases later in life. Despite the myriad of
concerns with adolescent tobacco use, little is known regarding the mechanisms that mediate
their enhanced vulnerability to tobacco use.

Tobacco use is motivated in large part by the rewarding effects of nicotine. Nicotine is a
natural pyridine alkaloid found in tobacco leaves and is most commonly burned and inhaled or
consumed via chewing tobacco-containing products (Pogocki et al., 2007). Studies investigating
the biological factors that motivate tobacco use have demonstrated that nicotine is the primary
reinforcing ingredient in tobacco products. This conclusion is based largely on the finding that
nicotine is readily self-administered by humans, primates, dogs and rodents (Corigall and Coen,
1989; Goldberg et al., 1981; Henningfield et al., 1985; Risner and Goldberg, 1983). In humans,
nicotine elicits positive emotional states such as elation and subjective feelings of euphoria that
enhance the likelihood of continued use (i.e., positive reinforcement). As an example, human
smokers given intravenous access to nicotine reported positive effects following infusions of
nicotine (Henningfield et al., 1983; Le Foll and Goldberg, 2009). Moreover, tobacco products
containing reduced nicotine levels were rated as less rewarding relative to cigarette brands
containing more nicotine (Rose and Behm, 2004a and 2004b).
2

Tobacco use is also motivated by avoiding the negative effects of withdrawal. Repeated
exposure to tobacco leads to nicotine dependence as defined in the Diagnostics and Statistical
Manual IV-TR. One of the hallmark characteristics of this disorder is the manifestation of a
withdrawal syndrome during periods of abstinence from tobacco. Adult smokers display adverse
withdrawal symptoms including craving, anxiety and negative affect. The emergence of these
subjective effects is closely associated with the severity of dependence and the likelihood of
smoking relapse (Hughes, 2007; Piper et al., 2011a and 2011b; Ríos-Bedoya et al., 2008; West et
al., 2006). The negative effects of withdrawal can be alleviated with pharmacological agents that
have been shown to promote abstinence (Bolt et al., 2012; Buchhalter et al., 2008; Lerman et al.,
2006). Given that withdrawal induces negative affective states, relapse behavior is thought to be
due to negative reinforcement processes driven by the avoidance of withdrawal states.
To summarize, adult tobacco use is mediated via experiencing the positive rewarding
effects of nicotine and avoiding the negative aversive consequences of nicotine withdrawal.
Thus, tobacco addiction in adults involves at least two processes. Initially, smoking is driven by
the strong positive rewarding effects of nicotine that promote continued use. With repeated
tobacco use, nicotine dependence develops and abstinence produces craving, which can lead to
relapse. Thus, an addicted state in adults is thought to reflect a dynamic shift in motivational
systems from positive to negative reinforcement processes that promote compulsive use of
tobacco and loss of control over drug use (Koob and Le Moal, 2001). Given the importance of
nicotine withdrawal in motivating tobacco use and relapse behavior, more research is needed to
understand the underlying mechanisms in the brain that mediate the nicotine withdrawal
syndrome.

3

Adolescent humans display enhanced rewarding effects of nicotine. To our knowledge,
the rewarding effects of nicotine have not been directly compared in adolescents versus adults in
a clinical setting. However, adult smokers that initiated smoking during adolescence reported
more pleasant effects and fewer unpleasant effects (e.g., dizziness and sickness) following their
first smoking episode. On the other hand, adults that initiated smoking in adulthood reported
more adverse symptoms following their first smoking episode (see Eissenberg and Balster, 2000;
Pomerleau et al., 1993, 1998, and 1999). There is also a myriad of social factors that contribute
to tobacco use during adolescence. The risk factors that promote tobacco use during adolescence
include enhanced risk-taking, peer pressure, media influence, and weight concerns (Henningfield
et al., 2011; Hussaini et al., 2011; Nizami et al., 2011). More research is needed to directly
compare the rewarding effects of nicotine in adolescents versus adults.

Adolescent humans display reduced nicotine withdrawal. A study comparing adolescent
smokers versus non-smokers found that young smokers exhibited mild symptoms during
withdrawal (i.e., anger and craving) that were not associated with self-reports of dependence or
biological markers of cigarette use (Smith et al., 2008a). A separate report from this laboratory
also found that withdrawal symptoms on the quit day were not related to relapse behavior in
adolescent smokers (Smith et al., 2008b). The latter findings suggest that nicotine withdrawal
may not be the primary motivating factor that drives adolescent tobacco use. Furthermore,
treatment strategies that focus on alleviating the negative effects of nicotine withdrawal, such as
the nicotine patch, do not improve abstinence rates in adolescent smokers (Bailey et al., 2012;
Grimshaw and Stanton, 2006; Hanson et al., 2003; Moolchan et al., 2005). Studies examining the
ability of a variety of tobacco cessation medications to produce abstinence in adults reported
4

success rates in the range of 19.0-36.5% whereas studies in adolescents reported success rates in
the range of 4.5-20.6% (see Bailey et al., 2012; Hudmon et al., 2010). One possible explanation
for these age group differences is that adolescents experience lower negative effects of
withdrawal during abstinence from nicotine. As a result, treatments that target withdrawal may
not reduce tobacco use in adolescents. These differences in withdrawal symptoms and treatment
outcomes suggest that the mechanisms that mediate nicotine withdrawal are fundamentally
different in adolescents versus adults.
To summarize, the factors that drive adult tobacco use involve experiencing the positive
rewarding effects of nicotine and avoiding the negative aversive effects of nicotine withdrawal.
A summary of the reviewed clinical data may suggest that adolescent tobacco use is driven by
motivational factors that are different from those described in adults. Namely, a hypothesis was
presented by O’Dell (2009) suggesting that enhanced vulnerability to tobacco use in adolescents
is driven by two factors: 1) the positive rewarding effects of nicotine are greater, and 2) the
negative aversive effects of nicotine withdrawal are reduced in magnitude relative to adults.
Thus, it is proposed that an inadequate balance between the strong positive rewarding effects of
nicotine that are unopposed by minimal negative effects during withdrawal enhances the
motivation to use tobacco products during adolescence. The proposed model of adolescent
tobacco use is supported by animal studies showing that adolescent rodents display enhanced
rewarding effects of nicotine and reduced aversive effects of withdrawal as compared to adults.

5

II. Animal Studies

Adolescent rodents display enhanced rewarding effects of nicotine. Rodent studies
provide strong evidence that the rewarding effects of nicotine are enhanced during adolescence.
For example, adolescents displayed enhanced preference for an environment repeatedly paired
with nicotine as compared to adults across a wide range of experimental protocols, nicotine
doses, and routes of administration (Belluzzi et al., 2004; Kota et al., 2007; Shram et al., 2006;
Shram and Le, 2010; Torres et al., 2008 and 2009; Vastola et al., 2002). Also, studies using both
intravenous and oral self-administration procedures have shown that nicotine intake is higher in
adolescent versus adult rats (Chen et al., 2007; Levin et al., 2003, 2007, and 2011; Nesil et al.,
2011) and mice (Adriani et al., 2002). Nicotine self-administration is also greater in adolescents
versus adult rats across a range of nicotine doses (Natividad, unpublished data). Taken together,
as suggested in the human clinical studies, this pre-clinical evidence supports the hypothesis that
the rewarding effects of nicotine are enhanced in adolescent versus adult rodents.

Animal models of withdrawal. Nicotine withdrawal has been widely studied in rodents
using chronic nicotine administration via subcutaneous osmotic mini-pumps (Kenny and
Markou, 2001; Malin, 2001; O’Dell et al., 2004, 2006 and 2007). Most studies examining
nicotine withdrawal use a protocol whereby rats are first prepared with pumps that deliver
nicotine for 5-7 days to produce dependence. Withdrawal is then assessed following the
cessation of nicotine via pump removal (i.e., spontaneous withdrawal) or administration of a
nicotinic acetylcholine receptor antagonist to disrupt nicotine binding on these receptors (i.e.,
precipitated withdrawal). The advantage of using nicotinic receptor antagonists such as
6

mecamylamine is that these drugs produce a discrete withdrawal with a well-established time of
onset that can be repeatedly induced. The onset of mecamylamine-induced withdrawal symptoms
begins within 10 minutes of administration in nicotine-treated rats (Malin et al., 1994).
Mecamylamine has a 1.2-hour blood half-life in rats, suggesting that it is quickly eliminated
(Debruyne et al., 2003). Studies in our laboratory have verified that withdrawal effects can be
repeatedly induced with mecamylamine in the same animals in a dose-dependent manner
(Natividad et al., 2010). Lastly, mecamylamine does not produce a withdrawal-like phenotype in
animals that are nicotine-naïve (O’Dell et al., 2004, 2006, and 2007; Hildebrand et al., 1998 and
1999). Collectively, these findings suggest that pharmacological blockade of nicotinic receptors
is a valid approach to study the effects of nicotine withdrawal.
Studies have demonstrated that the nicotine withdrawal syndrome is comprised of both
physical and affective components, as discussed in the following sections. For example, nicotinetreated adult rats display physical signs of withdrawal that include abdominal constrictions (e.g.,
writhes and gasps), facial fasciculation (e.g., teeth chattering and cheek tremors), eye blinks,
body shakes, head shakes, and ptosis (see Malin, 2001). These physical signs have also been
reliably demonstrated during withdrawal from other drugs of abuse such as morphine and
cocaine (Malin et al., 1987 and 2000).

Adolescent rodents display reduced nicotine withdrawal. Initial studies examining age
group differences in nicotine withdrawal demonstrated that mecamylamine precipitated fewer
physical signs of withdrawal in adolescent versus adult rats that received the same nicotine dose
in their pumps (O’Dell et al., 2004). Further studies that adjusted for metabolic differences to
nicotine verified that adolescents displayed fewer withdrawal signs versus adults with
7

comparable levels of blood nicotine (O’Dell et al., 2006). This is consistent with a report
showing that adolescent rats displayed fewer signs of nicotine withdrawal following
mecamylamine administration relative to adult rats that received equivalent nicotine doses to
produce dependence (Shram et al., 2008). The latter study also demonstrated that although
precipitated withdrawal produced robust age group differences, adolescent and adult rats
displayed similar physical signs of withdrawal during spontaneous withdrawal (i.e., pump
removal). Thus, it appears that precipitated withdrawal, which produces intense physical
symptoms, is a more sensitive method for detecting age group differences relative to spontaneous
withdrawal that only produces mild effects.
The affective properties of withdrawal have been studied using intracranial selfstimulation (ICSS) procedures. In ICSS studies, rodents are allowed to self-administer small
amounts of electrical current to the brain via an electrode placed in the medial forebrain bundle
that consists of efferent projections to several reward-related structures. The stimulation is highly
reinforcing and can be used to generate a threshold measure of the activity of brain
reinforcement circuitry. For example, it has been shown that withdrawal from many drugs of
abuse such as cocaine, alcohol and nicotine elicited an increase in self-administered current
(Chartoff et al., 2012; Chester et al., 2006; Watkins et al., 2000). The need for higher current
levels via increases in ICSS thresholds is believed to reflect a decrease in brain reward function
because the animal has difficulty experiencing pleasure during withdrawal.
Using ICSS procedures, changes in current intensity thresholds were compared in
adolescent and adult rats experiencing both precipitated and spontaneous nicotine withdrawal
(O’Dell et al., 2006). The results revealed that adult rats showed an increase in ICSS current
thresholds (which is interpreted as a decrease in brain reward function) following
8

mecamylamine-precipitated and spontaneous withdrawal conditions relative to naïve controls.
However, this effect was absent in adolescent rats. These data support the hypothesis that
adolescents experience less negative affect during nicotine withdrawal relative to adults. Further,
the negative affective properties of nicotine withdrawal were lower during spontaneous
withdrawal from nicotine, suggesting that the behavioral effects do not appear to depend on
differential sensitivity to mecamylamine.
In addition to ICSS procedures, the affective properties of nicotine withdrawal have been
studied using conditioned place aversion (CPA) procedures. In these studies, animals receive
chronic nicotine via osmotic pumps for 5-7 days. During conditioning, the animals receive a
nicotinic receptor antagonist to precipitate withdrawal and are then confined to one side of the
apparatus. On alternating days, the animals receive saline in the other compartment. Following
conditioning, nicotine-treated adult rats were observed to display an aversion to the compartment
where they experienced withdrawal (Ise et al., 2000; Suzuki et al., 1996 and 1999; Watkins et al.,
2000). Using these procedures, work in our laboratory demonstrated that the ability of nicotine
withdrawal to produce CPA was lower in adolescent versus adult rats (O’Dell et al., 2007).
The affective properties of nicotine withdrawal have also been examined with another
technique that measures anxiety-like behavior in rodents using elevated plus maze procedures.
This procedure assesses how rats respond to an approach-avoidance situation involving open
elevated spaces that are normally avoided versus enclosed safe areas that are inherently
preferred. Adult rodents experiencing nicotine withdrawal display an increase in anxiety-like
behavior, as indicated by a decrease in open-arm time relative to controls. However, the latter
effect was lower in adolescent rats (Wilmouth and Spear, 2006) and mice (Kota et al., 2007) as
compared to adults.
9

Taken together, as suggested in the human clinical studies, pre-clinical evidence supports
the hypothesis that the physical and negative affective properties of nicotine withdrawal are
reduced in adolescent versus adult rodents. The converging lines of evidence in clinical and preclinical work also suggest that rodent models are a valid approach to study the motivational
factors that drive human tobacco use.

Rationale for focusing on withdrawal mechanisms. The reviewed literature supports the
hypothesis that the rewarding effects of nicotine are enhanced whereas the aversive effects of
withdrawal from this drug are reduced during adolescence. Although the rewarding effects of
nicotine are a critical factor to study, the purpose of this dissertation was to explore age group
differences in the neurochemical mechanisms underlying the aversive effects of nicotine
withdrawal. This was done for several reasons. First, work in our laboratory showed that the
behavioral effects of nicotine withdrawal are lower in adolescent versus adult rats (O’Dell et al.,
2004, 2006 and 2007). By extension of these behavioral findings, the present studies explored
the hypothesis that the neural mechanisms mediating nicotine withdrawal are fundamentally
different in adolescents versus adults. Second, the present research reflects an extension of
previous work done by Natividad et al. (2010) showing that age group differences within
mesolimbic dopamine systems modulate age group differences in nicotine withdrawal. Lastly,
given the importance of nicotine withdrawal in motivating tobacco use and relapse behavior,
more research is needed to understand the underlying mechanisms in the brain that mediate
nicotine withdrawal. A better understanding of these mechanisms may contribute to the
development of specialized pharmacological tools to aid in tobacco cessation.
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This dissertation thesis addressed the following questions. Question #1: What are the
underlying neural mechanisms that mediate nicotine withdrawal? Question #2: Are there age
group differences in these mechanisms?

III. Mechanisms of Nicotine Withdrawal

This illustration depicts the mesolimbic pathway and inhibitory and excitatory
mechanisms that modulate dopamine transmission as discussed in the following sections.

Mesolimbic dopamine pathway. The mesolimbic pathway is generally thought to
mediate behavioral responses involving motivational processes for exogenous stimuli such as
food, sex, and drugs of abuse (see Wise, 2002). Dopamine transmission in this pathway is part of
a larger motivational circuit that mediates behavioral responses driven by positive and negative
reinforcement processes. This pathway, one of four major dopaminergic pathways in the brain,
originates in the ventral tegmental area (VTA) where a large cluster of dopamine neurons project
their axons forward to the nucleus accumbens (NAcc).

11

The present experiments focused on studying mechanisms in the VTA that modulate
NAcc dopamine transmission during nicotine withdrawal. The rationale for focusing on
mechanisms in the VTA is based on research showing that nicotine-treated rats displayed a
decrease in extracellular levels of NAcc dopamine following intra-VTA, but not intra-NAcc,
infusions of mecamylamine (Hildebrand et al., 1999; Hildebrand and Svensson 2000). Moreover,
intra-VTA infusions of nicotine produced a higher and more sustained increase in NAcc
dopamine levels relative to intra-NAcc infusions of nicotine (Nisell et al., 1994). The latter study
also showed that the ability of nicotine to increase NAcc dopamine was reversed by intra-VTA,
but not intra-NAcc, infusions of mecamylamine. Collectively, these findings support the
rationale for focusing on the VTA to study the neural mechanisms of nicotine withdrawal.
Dopamine transmission in the NAcc is influenced by dopamine cell excitability in the
VTA (Vos et al., 1999). In this regard, much interest has been expressed in studying the various
factors that influence excitability of the VTA dopamine cell bodies. Overall, this large body of
work has shown that NAcc dopamine transmission is modulated in the VTA by excitatory and
inhibitory mechanisms, as described below.
Excitatory mechanisms regulate mesolimbic dopamine. Glutamate is the most abundant
excitatory amino acid neurotransmitter in the brain (Meldrum, 2000). Glutamate binds to 2 main
receptor subtypes including N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA) receptors. Glutamate activates the opening of ion
channels that allow the passage of cations, such as sodium and potassium, to enter the cell
following their concentration gradient. This influx of positive current elevates the membrane
potential of the cell from its resting state (i.e., depolarization) toward the threshold of generating
action potentials and, as a result, is excitatory (Neuroscience: Exploring the Brain, 2001).
12

Increased frequency of action potentials generated via glutamatergic signaling produces
increased release of neurotransmitter.
The glutamatergic inputs to the VTA arise primarily from the prefrontal cortex, which
provides excitatory control of VTA neuron activity and enhances dopamine transmission in the
NAcc (Johnson et al., 1992; Kalivas et al., 1989; Mansvelder et al., 2003; Sesack and Pikel,
1992; Suaud-Chagny et al., 1992; Taber and Fibiger, 1995). The ability of glutamate to enhance
dopamine transmission is due to NMDA and AMPA receptors that are found on the somas of the
dopamine neurons in the VTA (Choi et al., 2011; Johnson et al., 1992; Mao et al., 2011; Paquet
et al., 1997; Schilstrom et al., 2006; Schumann et al., 2009). Local administration of glutamate
receptor agonists in the VTA induce dopamine burst firing (Harnett et al., 2009; Sombers et al.,
2009) and elevate extracellular levels of dopamine in the NAcc (Karreman et al., 1996;
Kretschmer, 1999; Westerink et al., 1996). On the other hand, glutamate antagonist
administration into the VTA reduces NAcc dopamine levels (Sombers et al., 2009; Westerink et
al., 1996). Collectively, these studies show that NAcc dopamine transmission is under excitatory
control of glutamate systems that innervate dopamine cell bodies in the VTA.

Inhibitory mechanisms also regulate mesolimbic dopamine. Gamma-aminobutyric acid
(GABA) is the major inhibitory neurotransmitter in the brain (Watanabe et al., 2002). GABA
binds to 2 main receptor subtypes including GABAA and GABAB receptors. GABA activates the
opening of ion channels that allow the passage of anions, such as chloride, to enter the cell
following their concentration gradient. This influx of negative current reduces the membrane
potential of the cell from its resting state (i.e., hyperpolarization) away from the threshold of
generating action potentials and, as a result, is inhibitory (Neuroscience: Exploring the Brain,
13

2001). Decreased frequency of action potentials generated by GABAergic signaling produces
decreased release of neurotransmitter.
Dopamine transmission in the NAcc is inhibited by GABAergic mechanisms in the VTA
via a population of GABA interneurons. In addition, there are also GABAergic projections back
from the NAcc and ventral pallidum that form synapses onto the VTA dopamine neurons
(Johnson and North, 1992; Kalivas, 1993; Mansvelder and McGehee, 2002; Mansvelder et al.,
2002; Rahman and McBride, 2002). The ability of GABA to inhibit dopamine transmission is
due to GABAA and GABAB receptors that are found on the somas of the dopamine neurons in
the VTA (Criswell et al., 1993; Cruz et al., 2004; Johnson et al., 1992; Johnson and North, 1992;
Labouèbe et al., 2007; Okada et al., 2004). Electrophysiological studies have shown that VTA
dopamine activity is elevated in the presence of GABA antagonists, and diminished with GABA
agonists (Xi and Stein, 1998). In agreement with these findings, microdialysis studies reported
that intra-VTA infusions of a GABA receptor antagonist increased extracellular dopamine levels
in the NAcc (Ikemoto et al., 1997; Natividad et al., 2010; Westerink et al., 1996). On the other
hand, GABA agonist administration into the VTA decreased NAcc dopamine levels (Westerink
et al., 1996). Collectively, these studies show that NAcc dopamine transmission is under
inhibitory control of GABA systems that innervate dopamine cell bodies in the VTA.
To summarize, the mesolimbic dopamine pathway consists of a collection of dopamine
cell bodies that are innervated by excitatory and inhibitory amino acid mechanisms in the VTA.
Dopamine cell excitability is altered in the VTA via excitatory glutamate and inhibitory GABA
systems, and changes in levels of these amino acids alter dopamine transmission in the NAcc.
The subsequent sections describe the effect of nicotine on the circuits of the mesolimbic
pathway.
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This illustration depicts the anatomical substrates by which nicotine alters dopamine
transmission as described in the following sections.

Nicotine alters mesolimbic dopamine. Nicotine binds to nicotinic acetylcholine receptors
(nAChRs) that consist of pentameric membrane proteins of homomeric or heteromeric
complexes of α or β subunits (see Mansvelder et al., 2002). Stimulation of these ligand-gated
receptors activates the opening of ion channels that allow the passage of cations to enter and
depolarize the cell, thereby inducing an excitatory response. nAChRs that are located on the presynaptic terminal have particular influence on neurotransmitter release because they stimulate
the opening of voltage-sensitive calcium channels that regulate exocytosis (McGehee and Role,
1995; Pidoplichko et al., 2004; Rathouz et al., 1996; Schilstrom et al., 2000).
To date, 12 isoforms have been identified (α2-10 and β2-4), and the various subunit
combinations give rise to functional differences in binding affinity, channel activation, calcium
permeability, and desensitization produced by nAChR agonists in general. The two most
pervasive and well-described nAChR subtypes in the brain are α7 and α4β2 nAChRs (Picciotto
et al., 2008). It has been shown that nicotine and other nAChR agonists display higher affinity
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binding for α4β2 relative to α7 subtypes (Lippiello et al., 1987; McGehee and Role, 1995; Papke
and Thinschmidt, 1998; Picciotto et al., 2008; Wonnacott, 1986). The significance of high
affinity binding onto α4β2 subtypes is that these receptors are highly susceptible to
desensitization. Thus, following prolonged agonist stimulation, the channel membrane associated
with α4β2 receptors remains in a closed conformational state, and agonists are no longer able to
activate these channels (see Jones and Westbrook, 1996).
nAChRs are anatomically positioned to alter dopamine transmission in the mesolimbic
pathway. These receptors are abundantly present in the VTA because of cholinergic projections
that arise from the pedunculopontine and laterodorsal tegmentum and innervate the VTA
dopamine neurons (see Omelchenko and Sesack, 2006). Three cell types in the VTA have been
shown to express nAChRs: dopamine neurons, GABA interneurons, and glutamate pre-synaptic
terminals (Mansvelder and McGehee, 2002; Xu et al., 2006). Dopamine neurons express α2-10
and β2-4 subunits (Mansvelder et al., 2003). Glutamate terminals in the VTA contain α7
nAChRs, whereas GABA cell bodies largely contain α4β2 sites (see Marchi et al., 2002;
Nomikos et al., 2000). The ability of these receptor subtypes to modulate NAcc dopamine
transmission has been demonstrated in the findings that intra-VTA administration of α7 or α4β2
selective antagonists blocked nicotine-induced increases in NAcc dopamine levels (Ericson et
al., 2003; Fu et al., 2000; Schilstrom et al., 1998).
Cholinergic transmission onto VTA GABA neurons can be reduced via the blockade of
nAChRs or via desensitization during nicotine exposure. When nicotine is administered, α4β2
nAChRs desensitize within minutes and recover very slowly from desensitization (Gentry et al.,
2003; Mansvelder and McGehee, 2002; Pidoplichko et al., 2004; Wang and Sun, 2005). In fact,
in the first 15 minutes after nicotine exposure, GABA neurons do not respond to nicotine
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application, and they take approximately 1 hour to return to normal levels of sensitivity
(Mansvelder et al., 2002). Thus, as a result of nicotine exposure, the VTA dopamine neurons
receive less inhibitory GABA transmission, and this decrease in inhibitory tone results in
enhanced action potential firing of the dopaminergic neurons. In contrast, α7 nAChRs that
modulate glutamate transmission are much less susceptible to desensitization during nicotine
exposure relative to α4β2 nAChRs (Wooltorton et al., 2003). The latter study was conducted at
low concentrations of nicotine (20-80 nM) to model the plasma levels of nicotine reported in
human smokers. In fact, the doses of nicotine that are self-administered in both humans and
animals often result in low nM brain concentrations, and this is believed to induce
desensitization of α4β2 to a larger degree than α7 nAChRs (see Grady et al., 2007; Buccafusco et
al., 2009; Mansvelder et al., 2002; Pidoplichko et al., 2004; Wooltorton et al., 2003).
Although the β2 heteromeric nAChRs became rapidly desensitized with low nicotine
concentrations, α7 sites on afferent glutamate terminals remain functional and facilitate the
release of glutamate onto the VTA dopamine cell bodies (Dani et al., 2001; Pidoplichko et al.,
2004; Schilstrom et al., 2000). Nicotine, therefore, induces a shift from inhibition towards
excitation of the VTA dopamine neurons that result in enhanced dopamine transmission in
reward circuits of the NAcc. Consistent with this, Yin and French (2000) demonstrated that VTA
GABAergic neurons displayed a lower electrophysiological response to nicotine, and in
sequential exposure, a more profound desensitization relative to those observed in dopamine
neurons. This rapid desensitization has been purported to lead to a disinhibition of the dopamine
neurons, thereby facilitating a more sustained increase in mesolimbic dopamine transmission
following nicotine. Collectively, these studies suggest that desensitization produced by nicotine
differentially affects α4β2 relative to α7 nAChRs in the VTA. The consequences of this
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desensitization is an imbalance of excitatory/inhibitory signaling, such that α4β2 receptors
located on GABAergic interneurons rapidly desensitize and attenuate inhibitory transmission. On
the other hand, α7 receptors located on glutamate pre-synaptic terminals do not desensitize and
instead facilitate excitatory transmission.
To summarize, nicotine binds to α4β2 receptors located on GABAergic interneurons, and
following chronic nicotine stimulation, these receptors desensitize and reduce GABA inhibition
of VTA dopamine neurons. On the other hand, nicotine binding to α7 receptors facilitates
excitatory glutamatergic transmission on the dopamine neurons. These reciprocal effects on
GABA and glutamate transmission converge on the dopamine cell bodies to enhance dopamine
cell excitability and facilitate an increase in NAcc dopamine transmission following nicotine
administration.

Neurochemical mechanisms of nicotine withdrawal. The allostasis theory of addiction
posits that drug-seeking behavior is mediated by the emergence of negative emotional states
produced by counteradaptive opponent processes that are left unopposed in the absence of the
drug (Koob and Le Moal, 2001). Following chronic drug use, Koob and Le Moal suggest that the
counteradaptive opponent processes that limit reward function fail to return to a normal
homeostatic range. This forms an allostatic state that represents a chronic deviation of the reward
set point that drives an enhanced state of vulnerability and results in loss of control over drug
use. Further, the theory proposes that neuroadaptations of withdrawal occur within the same
brain circuits that mediate the rewarding effects of the drug, but are opposite to the effects
produced by the drug itself. In light of the previous studies on nicotine, this model provides a
foundation for considering potential neurochemical processes that mediate nicotine withdrawal.
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As predicted by the allostasis theory, the increase in NAcc dopamine produced by drugs
of abuse (e.g., alcohol, opiates and cocaine) is followed by a decrease in NAcc dopamine once
the drug is removed and the direct effects of the drug subside (Pothos et al., 1991; Rada et al.,
2004; Weiss et al., 1992). This withdrawal effect has also been observed in nicotine-treated adult
rats that displayed a 20-35% decrease in extracellular levels of NAcc dopamine following
nAChR blockade with mecamylamine (Carboni et al., 2000; Gaddnas et al., 2002; Hildebrand et
al., 1998 and 1999; Natividad et al., 2010; Rada et al., 2001). The ability of mecamylamine to
reduce NAcc dopamine levels is believed to be due to the non-selective blockade of nAChRs
located on dopaminergic and non-dopaminergic neurons in the VTA. This is based on the finding
that intra-VTA, but not intra-NAcc infusions of mecamylamine, produced decreases in NAcc
dopamine and concomitant increases in physical signs of withdrawal (Hildebrand et al., 1999;
Hildebrand and Svensson, 2000).
To summarize, nicotine elicits increases in NAcc dopamine; however, withdrawal from
this drug produces a counteradapative decrease in NAcc dopamine. This finding reflects a
neuroadaptation in reward circuitry that is opposite to the effects produced by nicotine itself.
Currently, there is a significant knowledge gap regarding the neurochemical mechanisms that
mediate decreases in NAcc dopamine observed during nicotine withdrawal. In this regard,
candidate systems may include amino acid mechanisms in the VTA based on previous findings
that glutamate and GABA modulate VTA dopamine cell activity that project to the NAcc.
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IV. Dissertation Questions

Dissertation Question #1: Are the decreases in NAcc dopamine observed during
withdrawal modulated via amino acid mechanisms in the VTA? Nicotine produced elevations
in NAcc dopamine via amino acid mechanisms in the VTA (Mansvelder et al., 2002; Mansvelder
and McGehee, 2002). By extension, it was hypothesized that changes within the same
mechanisms regulate decreases in NAcc dopamine, but in a drug-opposite manner (i.e., opposite
to the effects produced by nicotine) during withdrawal. In accordance with the allostasis theory,
it was hypothesized that during nicotine withdrawal, excitatory transmission on the dopamine
cell bodies in the VTA is reduced (less glutamate in the VTA) whereas inhibitory transmission is
enhanced (more GABA in the VTA). Thus, these two simultaneous effects are hypothesized to
converge on the dopamine cell bodies to reduce NAcc dopamine levels during withdrawal.
A withdrawal mechanism involving reduced glutamate transmission is supported by the
finding that intra-VTA administration of a glutamate antagonist elicits morphine withdrawal
(Wang et al., 2004). Further, morphine withdrawal enhances presynaptic inhibitory mechanisms
in the VTA that regulate glutamate release, an effect that suggests that glutamate transmission is
reduced during withdrawal (Manzoni and Williams, 1999). Other work has demonstrated that
GABA transmission in the VTA is enhanced during withdrawal from several drugs of abuse,
including amphetamine (Giorgetti et al., 2002), cocaine, and morphine (Bonci and Williams,
1996 and 1997; Madhaven et al., 2012). Collectively, these studies suggest that VTA amino acid
systems play a role in mediating mesolimbic dopamine responses during drug withdrawal.
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This illustration depicts the hypothesized changes during nicotine withdrawal.
To summarize, it was hypothesized that during nicotine withdrawal, excitatory
glutamatergic transmission is reduced and inhibitory GABAergic transmission is enhanced in the
VTA. The effects of GABA and glutamate transmission are hypothesized to converge on the
dopamine cell bodies to reduce VTA dopamine cell excitability and decrease dopamine
transmission in the NAcc.

Dissertation Question #2: Is the amino acid modulation of dopamine during
withdrawal age dependent? Previous work in our laboratory demonstrated that mecamylamine
precipitated a lower magnitude of a decrease in NAcc dopamine levels of nicotine-treated
adolescent versus adult rats (Natividad et al., 2010). These data suggested that adolescent rats
were less sensitive to the neurochemical changes produced by nicotine withdrawal. The goal of
this dissertation was to extend these findings by examining whether age group differences in
NAcc dopamine during withdrawal were mediated by amino acid systems in the VTA.
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The illustration depicts the hypothesis that amino acid mechanisms underlie age group
differences in NAcc dopamine during nicotine withdrawal.

Specifically, it was hypothesized that diminished decreases in NAcc dopamine of
adolescent rats experiencing nicotine withdrawal is related to enhanced excitatory glutamate
(denoted as a larger glutamate neuron) and reduced inhibitory GABA (denoted as a smaller
GABA neuron) transmission in adolescent relative to adult rats. This age group difference in
amino acid transmission during nicotine withdrawal was hypothesized to minimize reductions in
dopamine cell excitability (denoted as a larger dopamine neuron) and prevent large decreases in
NAcc dopamine of adolescent versus adult rats.

V. Background Information Regarding Adolescence in Rats

In assessing the boundaries of the adolescent period in rodents, most researchers agree
that the prototypic age range for adolescence conservatively ranges from postnatal day (PND) 28
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to 45 (see Spear, 2000). Historically, it has been difficult to define an exact time frame of
adolescence since this phase of development is a transitional period that encompasses a series of
events with no single discrete event that signals its onset or termination, such as puberty that
signals sexual maturation. Adolescence reflects a period of “soft” events during which agespecific behavioral discontinuities from younger and older animals are most evident (Pickles et
al., 1998). Some of the behavioral characteristics that have established the period of adolescence
in rats include accelerated growth rates, emergence from the protected nest (Galef, 1981) and
enhanced social interaction (Primus and Kellogg, 1989), risk-taking and novelty-seeking
behavior (Spear et al., 1980, Spear and Brake, 1983). These innate age group differences are
important to consider when evaluating the behavioral effects of drugs of abuse in rats from
different stages of development.

VI. Background Information for Neurochemical Methods

The illustration depicts a microdialysis probe used to extract samples from the
extracellular environment in freely-moving animals (adapted from Chaurasia et al., 2007).
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In vivo microdialysis procedures. Microdialysis procedures allow an experimenter to
estimate changes in neurotransmission in the synapse of a discrete brain region. A probe
consisting of a semi-permeable membrane tip is inserted into the brain region of interest.
Artificial cerebral spinal fluid (ACSF) is delivered through the inlet of the probe at a constant
rate via a syringe pump. This creates a concentration gradient across the microdialysis membrane
such that molecules of a small enough size enter the probe tip via diffusion properties. The
ACSF containing the neurotransmitters (i.e., dialysate) is collected in an outlet vial at the probe.
The passage of molecules across the membrane tip is determined by the concentration of
neurotransmitter in the area where the probe is implanted, the flow rate of the perfusate, and the
size of the pores on the membrane tip. Typically, the external diameter of the membrane is about
250-300 µm with molecular weight cut-off of 6,000-20,000 Daltons. Dialysate samples that were
retrieved from the NAcc were examined for dopamine, and samples from the VTA were
examined for amino acid (i.e., glutamate and GABA) neurotransmitter content. It should be
noted that different techniques were employed to assay and quantify the neurotransmitters, as
described in the sections below.

Neurochemical methods for dopamine and amino acids. Different methods were used to
quantify dopamine and the amino acids in the present studies. High performance liquid
chromatography (HPLC) was used to measure dopamine because temporal resolution remains
high with this neurochemical assay without requiring a large amount of brain dialysate to be
injected into the system (Zapata et al., 2009). Capillary electrophoresis (CE) was used to separate
the small and highly polarized amino acid molecules that would have required a larger dialysate
volume (i.e., more sampling time) to assay with conventional HPLC methods. Thus, CE
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technology was used to ensure that similar dialysate collection strategies could be employed
across all neurochemical measures.

This illustration depicts how HPLC produces separation of analytes in a dialysate sample
(adapted from Lambertson, 2012).

Separation method for dopamine. HPLC is used to separate components of a sample
(i.e., analytes) via reverse-phase ion-pairing retention on a chromatographic column. This occurs
via the use of a pump apparatus that circulates a mobile phase solution at high pressure speed to
deliver the sample through a separation column. The column consists of tightly packed silicon
beads containing alkyl-carbon chains (i.e., stationary phase) that interact with the analyte based
on the polarity of the molecule. Thus, the elution time of the analyte from the column depends on
its ability to associate with the non-polarized elements of the stationary phase. For example, the
less polar the analyte, the better the electrons of this molecule will interact with those of the
column packing to enhance elution time from the column. The elution time is also a function of
the alkyl-carbon chain length in the column packing (e.g., 18-carbon chain length for dopamine
separation), the concentration of ion-pairing detergent (e.g., sodium dodecyl sulfate), the
concentration of the organic modifiers in the mobile phase (e.g., methanol), and the flow rate
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applied to the system. The time at which a specific analyte elutes is called retention time and is
considered to be a unique characteristic of the analyte.

Detection method for dopamine. HPLC is coupled with electrochemical detection for
quantification of the individual analytes such as dopamine. The electrochemical detector consists
of two electrodes that carry an electrical potential which is set to oxidize in one electrode and
reduce in the other as the separated analytes pass through the pre-set field potentials. Oxidation
and reduction produced by the field potentials then generate a measurable current via the release
and gain of electrons that reflects the quantity of the analytes. The electrical current is translated
into a computerized image of the reaction in peak format, which can be quantified and compared
against a current that is generated from a standard containing a known concentration of
dopamine. The area-under-the-curve or peak heights from a series of standard injections are
linearly related to the amount of analyte. Thus, a linear regression of these standard injections is
used to predict the amount of analyte in a sample containing an unknown quantity.

This illustration depicts how CE separates analytes in a dialysate sample (adapted from
Principles of Instrumental Analysis, 2007).
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Separation methods for amino acids. The CE method involves the use of a high voltage
supply to generate an electrical potential between two conductive buffers that are separated by a
silicon capillary tube. These buffers generate an electrostatic drive that causes positively charged
ions (i.e., cations) to migrate from a sample towards the buffer containing a negative charge (i.e.,
cathode), whereas negatively charged ions (i.e., anions) are strongly retained in the positively
charged buffer (i.e., anode). The size of the analyte also allows for smaller molecules to migrate
faster along the capillary tube relative to larger molecules (i.e., hydrodynamic radius). Moreover,
the modification of chemical constituents along the capillary wall forms a secondary layer of
ionic species that interact with the charged elements of the analyte to facilitate electrophoretic
mobility (i.e., electro-osmotic flow). As an example, the addition of sodium hydroxide (that
carries a negative charge) along the capillary wall allows analytes that are positively charged to
migrate against the repelling forces of the anode so that they may be separated distinctly from
other cation molecules. This chemical adjustment is helpful in the separation of amino acids that
display low electrophoretic mobility. The order in which the separated analytes migrate forward
to the detector at the end of the capillary tube is considered a unique characteristic of each
molecule.

Detection methods for the analysis of amino acids. CE technology is often paired with
laser-induced fluorescence (LIF) detection to quantify amino acid compounds. Typically, the
detection of amino acids such as glutamate and GABA requires a derivatizing process that
combines the use of reducing and fluorescent chemical agents to attach a fluoroform to the
amino acid. The derivatized molecule is then excited by a focused laser beam that causes the
fluoroform to emit light at a specific wavelength which is captured by a detector. The intensity of
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the fluorescence, which is linearly related to the concentration of the fluoroform, is sent to a
computer interface that visualizes the data in peak format, and this can be quantified and
compared against the wavelength generated from standards containing a known concentration of
the amino acid of interest. The area-under-the-curve or peak heights from a series of standards
are linearly related to the amount of analyte. Thus, a linear regression of these standards is used
to predict the amount of analyte in a sample containing an unknown quantity.
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Chapter 2: Methods

I. Experimental Overview

This illustration depicts the experimental cohorts that were used in the dissertation
experiments.

The first experimental cohort included a group of nicotine-treated adolescent and adult
animals experiencing nicotine withdrawal with a dialysis probe in the NAcc to measure
dopamine and another probe in the VTA to measure amino acids. The NAcc dopamine data were
published as an important first step in elucidating the role of mesolimbic dopamine in mediating
age group differences in nicotine withdrawal (Natividad et al., 2010). The current studies
extended the proposed neurochemical hypothesis by assessing concomitant measures of VTA
amino acids in order to explain age group differences in NAcc dopamine during withdrawal. An
additional cohort of animals was used to examine whether our method of precipitating nicotine
withdrawal (i.e., mecamylamine) alone produced neurochemical changes. To address this
question, a group of nicotine naïve adolescent and adult rats were included to examine changes
in NAcc dopamine levels following mecamylamine administration. The procedures used for
these cohorts are described below.
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II. General Methods

Animals. Male Wistar adolescent and adult rats (n=6-14 per group) were used.
Adolescents were PND 28 and adults were PND 60 at the start of the experiment. All rats were
handled for 5 days prior to the start of experimentation and were given free access to food and
water throughout the study. Rats were housed in groups of 2-3 per cage in a humidity- and
temperature-controlled (20-22oC) vivarium using a 12-/12-hour light/dark cycle with lights on at
8:00 AM. The home cages consisted of a rectangular Plexiglas® hanging cage (41.5 cm long x
17 cm wide x 21 cm high) with pine bedding. The food and water were located above the
animals’ living spaces on a wire platform encased within a filtered top cover. Testing procedures
were conducted during the light phase of the rats’ light/dark cycle. The rats were bred in the
Psychology Department from a stock of out bred Wistar rats from Harlan, Inc (Indianapolis, IN).
All procedures were approved by the UTEP Animal Care and Use Committee and followed the
guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory
Animals.

Drugs. The drugs used in these experiments were (-) nicotine-hydrogen tartate and
mecamylamine-hydrochloride purchased from Sigma Aldrich Inc. (St. Louis, MO).
Mecamylamine was dissolved in 0.9% sterile saline and injected via the intraperitoneal (ip) route
of administration in a volume of 1 ml/kg. To minimize pain and discomfort following surgeries,
animals were given a 2.5 mg/kg dose of flunixin meglumine via the subcutaneous route of
administration (Vedco, St Joseph, MO).
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III. Dialysis Methods

This illustration depicts the timeline of experimental procedures and ages of the animals.

Rats were first anesthetized with an isofluorane/oxygen mixture (1-3% isofluorane) prior
to undergoing sham surgery or surgical implantation of 14-day Alzet osmotic pumps purchased
from Durect Corporation (Alzet model 2ML2; 5.0 µl/hour; Cupertino, CA) that were implanted
subcutaneously on the back of the animal, parallel to the spine. Pumps were filled with an
adjusted concentration of nicotine (4.7 mg/kg/day for adolescents or 3.2 mg/kg/day for adults;
expressed as base). The concentration of nicotine in the pump was adjusted according to the
weight of the rat at the time of the surgery. The nicotine doses were based on previous work
showing that adolescent rats require approximately 1.5 times more nicotine to display similar
plasma nicotine levels as adults (O’Dell et al., 2006). After surgery, the surgical incision was
closed with 9-mm stainless steel wound clips and treated with a topical antibiotic ointment, and
the animals received an injection of flunixin (sc) to minimize pain and discomfort.
Thirteen days after pump implantation, the rats were implanted unilaterally with 2 probes
into the NAcc and the ipsilateral VTA. All rats were implanted with probes between postnatal
day 40 for adolescents and postnatal day 72 for adults. The probes were purchased from CMAMicrodialysis (model CMA 11; Solna, Sweden) with an active membrane length of 2 mm in the
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NAcc and 1 mm in the VTA. The probes were perfused for at least 1 hour prior to implantation
at a rate of 0.5 µl/minute with ACSF composed of 145 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2,
1.2 mM MgCl2, 5.4 mM d-glucose, and 0.25 mM ascorbic acid and adjusted to a pH of 7.2-7.4.
The probes were stereotaxically implanted using the following coordinates for the NAcc from
bregma [adolescent placement- anterior-posterior (AP) = +2.2, medial-lateral (ML) = ±1.0,
dorsal-ventral (DV) = -7.1; and adult placement- AP = +1.7, ML = ±1.4, DV = -8.1] and the
ipsilateral VTA [adolescent placement- AP = -4.0, ML = ±0.6, DV = -7.4; and adult placementAP = -4.8, ML = ±0.8, DV = -8.5]. The hemisphere that was implanted with the probe was
randomized across treatment groups to control for possible hemispheric differences across age
groups.
Following surgery, adolescent and adult animals were transferred to similar sized test
cages (24 cm long x 24 cm wide x 31 cm high) with pine bedding. The perfusate flow rate was
increased to 1 µL/minute for 1 hour to allow equilibration of the probes. Samples were then
collected in 10-minute intervals for 1 hour to establish a baseline period, and then for 3 separate
1-hour collection periods following a systemic injection of saline and then 2 doses of
mecamylamine in increasing order (1.5 and 3.0 mg/kg, expressed as salt; ip). Microdialysis
testing was done in the continuous presence of nicotine that was distributed via the pumps.
Dialysate samples collected from the NAcc probe in naïve animals were diluted with 10 µl of
perchloric-acid (0.05 N) in order to preserve the samples and prevent degradation of dopamine.
After collection, the samples were immediately frozen on dry ice and were then stored in a -80oC
freezer until they were analyzed.
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IV. Neurochemical Methods

Dialysate dopamine content was estimated from a 10-µl sample injected into a HPLC
system equipped with an ESA HR-80 80x4.6 mm column (3 µm BetaBasic packing material,
carbon-18 stationary phase, Chelmsford, MA) and eluted using a mobile phase composed of a 60
mM NaH2PO4, 30 mM citric acid, 0.1 mM sodium-EDTA, 17% methanol, and 0.035 mM
sodium dodecyl sulfate at pH 3.75 delivered at 1 ml/minute by an ESA model 582 syringe pump
(Chelmsford, MA). Quantification was achieved via an ESA Coulochem II detector equipped
with a coulometric sensor containing dual glassy carbon working electrodes (model 5011A;
Chelmsford, MA) set to oxidate on the first channel at +350 mV and reduce on the second
channel at -150 mV. The extracellular levels of dopamine were estimated using external
calibration curves with standards containing known concentrations of these neurochemicals.
Dialysate amino acid content was estimated using CE technology. Derivatization of the
amino acids was achieved by mixing 6 µL of dialysate with 9 µL of 40 mM borate buffer (pH
10.5) containing 3.8 mM potassium cyanide and 1 µL of 5 mM naphthalene-2,3dicarboxaldehyde in methanol. The derivatized dialysate was then loaded onto a 90 cm fused
silica capillary and the amino acids were separated using +15 kV and a background electrolyte
solution consisting of 100 mM borate buffer (pH 9.2) containing 30 mM sodium dodecyl sulfate
and 2 mM hydroxypropyl-β-cyclodextrin. The amino acids were detected using a LIF detector
(Zetalif, Picometrics, Ramon Ville, France) equipped with a 442 nm helium-cadmium laser (30
mW, Melles Griot, Carlsbad, California). External calibration standards were run in duplicate
and were interspersed throughout the sample run.
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V. Histology Methods

At the end of the experiment, rats were deeply sedated with pentobarbital (100 mg/kg,
salt; ip) and perfused using 0.85% saline and then a 4% paraformaldehyde solution. Following
the perfusion, the brains were extracted and stored in formalin solution until they were sectioned.
Verification of the probe placements was achieved during tissue sectioning using the Paxinos
and Watson (1986) atlas. The probe placements were focused in the NAcc core region for both
adolescents and adults, as determined during sectioning of the brain tissue. The VTA placements
were all confined in this small brain region. In addition, an intra-VTA perfusion of bicucullinemethochloride (100 μM) using reverse dialysis procedures produced strong ipsilateral turning in
all of the animals, and this effect provided neuroanatomical verification since other studies have
reported similar results (Grubb et al., 2002; Westerink et al., 1996).

VI. Statistical Methods

Repeated-measures analysis of variance (ANOVA) was first conducted to examine
whether there were age group differences across the 6 baseline samples of dopamine, glutamate,
and GABA. The data revealed that there were no age group differences in basal levels of these
neurochemical measures. The subsequent analyses were conducted on values that were converted
to % change from baseline [i.e., (dialysate value/average baseline value) x 100%] in order to
demonstrate the magnitude of changes in these neurochemicals on a similar scale and also to
clearly illustrate group differences across experimental conditions. The dialysate data as %
change from baseline were then analyzed using repeated-measures ANOVA with age group
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(adolescent and adult) as a between-subject factor and time (10-minute intervals) as a withinsubject factor. Wherever appropriate, significant interaction effects were further analyzed using
Fisher’s protected least significant difference tests with a modified Bonferroni correction factor
for alpha inflation (p≤0.05).
To examine whether amino acid levels in the VTA modulate age group differences in
NAcc dopamine during nicotine withdrawal, regression analyses was performed between %
change in VTA glutamate or GABA, against % change in NAcc dopamine in the samples
collected before (i.e., baseline and saline) and after both doses of mecamylamine. A comparison
of amino acid with dopamine transmission was conducted only in the nicotine-treated animals
that had concomitant measures of these neurochemicals (n=7 per age group). Pearson
correlations (r) were conducted on the average of % baseline value for each dialysate fraction of
amino acid against each dialysate fraction of dopamine before and after mecamylamine
administration. To compare age group differences, the Pearson correlations were converted to
Fisher’s z scores and then compared by age group.
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Chapter 3: Results

Figure 1 illustrates % change in extracellular levels of NAcc dopamine (± SEM)
following mecamylamine administration in nicotine-naïve adolescent and adult rats. This
experimental cohort examined whether mecamylamine alone produced changes in NAcc
dopamine in drug-naïve adolescent and adult rats. Overall, the results revealed that
mecamylamine did not produce any alterations in NAcc dopamine across control groups of both
age groups. Baseline dopamine levels were not different between adult (2.3 ± 0.2 nM) and
adolescent (1.9 ± 0.3 nM) rats [F(1,10)=1.3; p=ns]. There were no main effects of time
[F(23,230)=0.1; p=ns] or age group [F(1,10)=0.04 p=ns]. An interaction between time and age
group was also not observed [F(23,230)=0.3; p=ns].
Figure 2 illustrates % change in extracellular levels of VTA glutamate (± SEM) in
nicotine-treated adolescent and adult rats experiencing nicotine withdrawal. The analyses reflect
a separate experimental cohort that examined age group differences in VTA amino acid levels in
adolescent and adult animals experiencing nicotine withdrawal. Overall, the results revealed that
mecamylamine produced a decrease in VTA glutamate in nicotine-treated adult but not
adolescent rats. Baseline glutamate levels were not different between adult (881.5 ± 135.1 nM)
and adolescent (952.4 ± 82.8 nM) rats [F(1,19)=0.2; p=ns]. A significant main effect of time
[F(23,437)=10.0; p≤0.05], age group [F(1,19)=8.5; p≤0.05], and interaction between time and
age group [F(23,437)=3.5; p≤0.05] was observed, with adults, but not adolescents displaying a
decrease in glutamate following mecamylamine. Specifically, adult rats displayed a maximal
decrease in VTA glutamate (43.6 ± 6.9% from baseline) that was larger relative to adolescents
that displayed a small but non-significant decrease in glutamate (10.4 ± 9.7% from baseline).
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Subsequent post-hoc analyses revealed that adult rats displayed a significant decrease in
glutamate relative to baseline at the 3rd-12th time points (*p≤0.05) and as compared to
adolescents at the 6th-12th time points after mecamylamine (†p≤0.05).
Figure 3 illustrates % change in baseline extracellular levels of VTA GABA (± SEM) in
nicotine-treated adolescent and adult rats experiencing nicotine withdrawal. Overall, the results
revealed that mecamylamine produced an increase in VTA GABA in nicotine-treated adult but
not adolescent rats. Baseline GABA levels were not different between adult (44.4 ± 3.7 nM) and
adolescent (38.3 ± 4.4 nM) rats [F(1,19)=0.8; p=ns]. An interaction between time and age group
[F(23,437)=1.8; p≤0.05] was observed, with adults, but not adolescents displaying an increase in
GABA following mecamylamine. Specifically, adult rats displayed a maximal increase in VTA
GABA (38.2 ± 17.2% from baseline) and adolescents were unchanged. Subsequent post-hoc
analyses revealed that adult rats displayed a significant increase in GABA levels relative to
baseline at the 1st and 9th time points (*p≤0.05) and as compared to adolescents at the 1st, 4th,
and 9th time points after mecamylamine (†p≤0.05).
The overall goal of these studies was to provide a better understanding of age group
differences in the neurochemical mechanisms of nicotine withdrawal. The following regression
analyses were done in order to help guide an overarching hypothesis regarding the manner in
which VTA amino acids regulate age group differences in NAcc dopamine.
Figure 4 is a scatter plot illustrating % change in baseline extracellular levels of VTA
glutamate plotted against NAcc dopamine in nicotine-treated adult versus adolescent rats before
and after mecamylamine administration. Overall, the results revealed that neither age group
displayed a significant correlation between VTA glutamate and NAcc dopamine before
mecamylamine administration. Following mecamylamine administration, however, adults
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displayed a significant correlation in VTA glutamate and NAcc dopamine, and this effect was
not observed in adolescent rats. Specifically, adults displayed a positive correlation between
VTA glutamate and NAcc dopamine, such that decreases in glutamate were associated with
decreases in NAcc dopamine (r= 0.90; p≤0.05). Also, the correlation between glutamate and
dopamine was stronger in adults (p≤0.05), and accounted for a larger proportion of the variance
(R2= 0.82) relative to adolescents (R2= 0.30).
Figure 5 is a scatter plot illustrating % change in baseline extracellular levels of VTA
GABA plotted against NAcc dopamine in nicotine-treated adult versus adolescent rats before and
after mecamylamine administration. Overall, the results revealed that neither age group
displayed significant correlations of VTA GABA and NAcc dopamine before mecamylamine
administration. Following mecamylamine administration, however, adult rats displayed a
significant correlation in VTA GABA and NAcc dopamine, and this effect was not observed in
adolescent rats. Specifically, adults displayed a negative correlation such that increases in VTA
GABA were associated with decreases in NAcc dopamine (r= -0.66; p≤0.05). In contrast,
adolescents did not display a significant correlation of these neurotransmitters. Also, the
correlation between GABA and dopamine was stronger in adults (p≤0.05) and accounted for a
larger proportion of the variance (R2= 0.42) as compared to our analysis in adolescents (R2=
0.14).
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Chapter 4: Discussion

I. Summary

Previous work in our laboratory demonstrated that nicotine withdrawal produces a
decrease in extracellular NAcc dopamine levels that is larger in adult versus adolescent rats. The
present studies expanded on these initial findings in three important ways. First, mecamylamine
did not produce alterations in NAcc dopamine levels in nicotine naïve adult or adolescent rats.
This validates the use of mecamylamine as a pharmacological tool to precipitate withdrawal in
nicotine-treated rats because the use of mecamylamine alone does not appear to confound the
results of the observed neurochemical measures. Second, nicotine withdrawal produces a
decrease in glutamate and an increase in GABA in the VTA of adults. On the other hand,
adolescents do not display significant changes in either of these amino acids in the VTA during
nicotine withdrawal. Third, as expected, due to the excitatory effects of glutamate on dopamine
cell bodies, decreases in VTA glutamate and decreases in NAcc dopamine were positively
correlated in adult rats, whereas adolescents did not display a significant correlation during
withdrawal. This correlation was stronger in adults versus adolescents. Also, as expected, due to
the inhibitory effects of GABA on dopamine cell bodies, increases in VTA GABA and decreases
in dopamine were negatively correlated in adults, whereas adolescents did not display a
significant correlation during withdrawal. This correlation was also stronger in adults versus
adolescents. Taken together, the results indicate that adult rats display changes in the
neurochemical processes that inhibit mesolimbic dopamine function during nicotine withdrawal.
However, adolescents show less pronounced amino acid control of the VTA dopamine cell
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bodies and lower withdrawal-related inhibition of mesolimbic dopamine function as compared to
adults.

II. Mechanisms of Nicotine Withdrawal in Adults

This illustration depicts the hypothesized mechanisms of nicotine withdrawal in adults.

The decreases in NAcc dopamine observed during withdrawal are modulated via amino
acid mechanisms in the VTA. Adult rats experiencing nicotine withdrawal display reduced
extracellular glutamate and enhanced GABA levels in the VTA. A significant proportion of
variance in the decreases in NAcc dopamine were accounted for by decreases in VTA glutamate
(R2= 0.82) and increases in VTA GABA (R2= 0.42). These effects likely reflect adaptations in
the mechanisms that modulate VTA cell excitability in response to long-term nicotine-induced
dopamine cell activation. The proposed theoretical framework suggests that upon clearance of
nicotine (or blockade of nicotinic receptors), these neuroadaptations are left unopposed, and this
results in an overall inhibition of VTA cell activity and a reduction in NAcc dopamine levels.
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These observations in adult rats are consistent with previous reports showing a similar
pattern of changes in glutamate and GABA in the VTA during withdrawal from other drugs of
abuse. For example, a withdrawal mechanism involving reduced glutamate transmission is
supported by the finding that intra-VTA administration of a glutamate antagonist elicited
morphine withdrawal (Wang et al., 2004). Further, morphine withdrawal enhanced pre-synaptic
inhibitory mechanisms in the VTA that regulate glutamate release, an effect that suggests that
glutamate transmission is reduced during withdrawal (Manzoni and Williams, 1999).
Other work has demonstrated that GABA transmission in the VTA is enhanced during
withdrawal from several drugs of abuse, including amphetamine (Giorgetti et al., 2002), cocaine,
and morphine (Bonci and Williams, 1996 and 1997; Madhavan et al., 2010). These studies
suggest that VTA amino acid systems play a role in mediating mesolimbic dopamine responses
during nicotine withdrawal. Specifically, these data suggest that during withdrawal from drugs of
abuse, dopamine cell bodies in the adult VTA are subject to diminished excitatory glutamate
signaling and enhanced inhibitory GABAergic tone. Collectively, these processes likely
contribute to reduced activity of mesolimbic dopamine projection neurons and decreases in
NAcc dopamine levels.
It is unclear whether nicotine withdrawal precipitated by mecamylamine produces
neurochemical differences that are distinct from those accompanied by spontaneous withdrawal.
Mecamylamine was used in this experiment because nicotinic receptor blockade elicits a discrete
and profound withdrawal in rats. Thus, relative to the removal of chronic nicotine that elicits a
mild withdrawal, mecamylamine produced a maximal withdrawal to study the underlying
mechanisms that mediate nicotine withdrawal. It is expected that similar neurochemical results in
adult rats (albeit, at a lower magnitude) would be observed under spontaneous nicotine
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withdrawal, since tissue dopamine content in the nucleus accumbens of adult rats has been
shown to decrease 24 hours following the removal of chronic nicotine (Fung et al. 1996).

III. Age Group Differences in the Mechanisms of Withdrawal

This illustration depicts our hypothesis regarding age group differences in amino acid
regulation of NAcc dopamine during nicotine withdrawal.

Amino acid modulation of dopamine during withdrawal is age dependent. A major
finding of the present study is that adolescent rats do not exhibit overall increases in VTA
inhibitory tone during precipitated nicotine withdrawal. Specifically, in contrast to adults, there
were no significant changes in either VTA glutamate or GABA transmission in adolescents
during withdrawal. Moreover, adolescents did not display significant correlations between NAcc
dopamine and VTA glutamate or GABA. This suggests that underdeveloped inhibitory
regulation of NAcc dopamine in adolescents may be responsible for age group differences in
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withdrawal. Relative to an adult experiencing withdrawal, adolescents exhibited enhanced
excitatory and reduced inhibitory modulation of the dopamine cell bodies in the VTA. This age
group difference in amino acid transmission during nicotine withdrawal is suggested to minimize
reductions in dopamine cell excitability and prevent large decreases in NAcc dopamine of
adolescent versus adult rats.

Rationale for enhanced glutamate and reduced GABAergic modulation of dopamine
during adolescence. Developmental studies have suggested that the period of adolescence is
characterized by enhanced excitatory and reduced inhibitory systems. Thus, it is possible that
this age-related imbalance toward excitation in adolescents buffers against the decreases in
excitation and increases in inhibition observed in the VTA during nicotine withdrawal in adults.
With respect to enhanced excitatory systems during adolescence, excitatory amino acid
pathways undergo transient overshoots and overproduction of glutamate terminals during
adolescence (de Graff-Peters and Hadders-Algra, 2006; McDonald and Johnston, 1990). For
example, glutamate innervation of the frontal cortex is overproduced during early postnatal
periods in rats (7-14 days) and humans (1-2 years; see Herlenius and Lagercrantz, 2004).
Although pruning of excitatory projections occurs during adolescence, increased density of
glutamate receptors and overproduction of synapses support the hypothesis that adolescence
reflects a period of enhanced glutamate cortical innervation (Dunah et al., 1996; Herlenius and
Lagercrantz, 2004). Other research has shown that the presence of glutamate receptors such as
NMDA is ubiquitously expressed in the immature brain to drive synaptic plasticity (Lujan et al.,
2005). In fact, the NR2B NMDA receptor subunit is highly expressed in early development, and
is suggested to enhance activation of cation channels and increase the ability of glutamate to
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strengthen synapses. Thus, enhanced excitatory regulation of the mesolimbic pathway may partly
explain why adolescents experience lower deficits in NAcc dopamine transmission relative to
adults during nicotine withdrawal.
With respect to reduced GABA systems during adolescence, before taking on its role as
an inhibitory neurotransmitter, GABA serves as a trophic factor during early development of
neural organization (see Kellogg, 1998). Although GABA is the main inhibitory transmitter in
the mature brain, paradoxically, it is an excitatory neurotransmitter in early postnatal life (BenAri et al., 1997; Cherubini et al., 1991; Lujan et al., 2005; Rivera et al., 1999). This is due to an
inverted chloride gradient early in development (Herlenius and Lagercrantz, 2004). In young
nerve cells, the chloride concentration is high such that when GABA activates chloride channels,
these anions exit the cell following their concentration gradient and induce an excitatory
depolarization response. However, during maturation, the chloride concentration reverses so that
these anions are present at higher concentrations outside the cell. Thus, the opening of chloride
channels by GABA allows these anions to enter the cell following their concentration gradient to
produce an inhibitory hyperpolarization response. In this way, GABA switches from being an
excitatory to inhibitory neurotransmitter in the developing brain.
Electrophysiological studies have also demonstrated that during adolescence, inhibitory
postsynaptic potentials (IPSP) in GABA neurons are slower, less frequent, and weaker in
response to GABA agonists relative to neurons from more mature animals (see Cohen et al.,
2000). The latter report demonstrated that by postnatal day 21, GABA agonist-induced IPSPs are
still weak reflecting continued immaturity in synaptic structure and function persisting through
adolescence. Also, GABA-mediated inhibition by postsynaptic GABAB receptors is not
functional early in life and GABA currents in neonatal rat neurons are insensitive to
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benzodiazepine activation of GABAA receptors, suggesting that there is immaturity in synaptic
function during early development (Cherubini et al., 1991). The excitatory role of GABA
switches to inhibition around 1 week after birth in the hippocampus and about postnatal day 7-14
in the frontal cortex of rat brain (Miles, 1999; Rivera et al., 2005). Although this time frame
precedes the period of adolescence described here, it is suggested that GABA systems in
adolescents may not be fully developed to inhibit VTA dopamine neurons. To further support
this suggestion, intra-VTA administration of a GABAA antagonist in adolescents produced a
lower increase in extracellular levels of NAcc dopamine relative to adults (Natividad et al.,
2010). Also, the ability of toxic doses of ethanol to enhance IPSPs in GABA neurons was
reduced in adolescent relative to adult rats (Li et al., 2006). Thus, reduced GABA-mediated
inhibition of the mesolimbic pathway may partly explain why adolescents experience lower
deficits in NAcc dopamine transmission relative to adults during nicotine withdrawal.

Alternative explanations for age group differences during withdrawal. The following
section provides a consideration of alternative explanations/mechanisms than those presented
above. Given that adolescence is characterized by enhanced excitatory and diminished inhibitory
transmission, it is surprising that age group differences in basal levels of the amino acids were
not observed. This quandary may reflect innate age group differences in the metabolism/uptake
of these amino acids, and/or neurotoxic-specific effects of nicotine that may have normalized age
group differences in basal neurochemistry. It is possible that our findings during withdrawal
relate to changes in glial release of amino acids. In this regard, structural remodeling of
neuroglial networks has been reported in the prefrontal cortex of adolescent rats repeatedly
treated with methylphenidate (Cavaliere et al., 2012). Thus, nicotine-induced changes in glial
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glutamate transporters may play a role in mediating age group differences in the neurochemical
effects of nicotine withdrawal. It may also be possible that other mechanisms involved in
nicotine-induced neuroadaptations are underdeveloped in the adolescent brain. For example, the
onset of dopamine D2-mediated regulation of prefrontal cortex network activity occurs during or
after adolescence (Tseng and O’Donnell, 2007) and this late-developing mechanism may also
provide important inhibitory regulation of excitatory glutamate projections to the VTA (Harte
and O’Connor, 2004).
The role of nicotinic receptors in mediating age group differences in the neurochemical
effects of nicotine withdrawal is not well understood. Electrophysiological studies have shown
that nicotine alters VTA glutamate and GABA transmission via binding to α7 and α4β2 nAChRs.
Specifically, nicotinic binding to α7 receptors located on VTA glutamate terminals facilitates
glutamate transmission, whereas nicotine quickly desensitizes α4β2 receptors located on VTA
GABA interneurons (Dani et al., 2000; Mansvelder and McGehee, 2002; Mansvelder et al.,
2002; Pidoplichko et al., 1997). The net effect is an imbalance of amino acid transmission
characterized by enhanced VTA glutamate and reduced GABA transmission that facilitates
NAcc dopamine transmission. The findings of this report during withdrawal show a drugopposite pattern in these amino acid systems of adult rats (i.e., reduced VTA glutamate and
enhanced GABA levels). The finding that these effects were otherwise absent in adolescents may
suggest that age group differences in nicotinic receptors underlie diminished changes in amino
acids levels during withdrawal. In fact, chronic nicotine has been shown to enhance nicotinic
receptor binding on α7 and α4β2 receptors to a larger magnitude in adolescents versus adults
(Doura et al., 2008; Levin et al., 2007; Trauth et al., 1999; Slotkin et al., 2004). Thus, enhanced
nicotinic receptors that have been previously shown to modulate amino acid activity in the VTA
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may begin to describe why adolescents display resistance to decreases in NAcc dopamine during
nicotine withdrawal. Future studies might examine the involvement of α7 and α4β2 receptors in
mediating age group differences in the neurochemical effects of nicotine withdrawal.

Are all nicotine-induced effects diminished during adolescence? It is important to note
that not all nicotine-induced adaptations are impaired in adolescent rodents. For example,
unpublished studies in our laboratory have shown that extracellular levels of acetylcholine in the
NAcc are increased in a similar manner during nicotine withdrawal in adolescent and adult rats.
Although withdrawal-induced increases in cholinergic transmission were similar across these age
groups, baseline levels of NAcc acetylcholine were higher in nicotine-treated adolescents versus
adults. In the same regard, adolescents display enhanced neurochemical and molecular responses
in the mesolimbic reward pathway following nicotine as compared to adults. For example, acute
nicotine enhanced long-term potentiation processes modulated by AMPA receptors in the VTA
of adolescent versus adult mice (Placzek et al., 2009). Nicotine also stimulated a greater release
of [3H] dopamine in striatal synaptosomes of adolescent versus adult rats (Azam et al., 2007).
Lastly, nicotine increased extracellular levels of NAcc dopamine to a larger magnitude in
adolescent versus adult rats (Shearman et al., 2008). Thus, it is suggested that adolescents may
have heightened expression of mechanisms involved in mediating the positive rewarding effects
of nicotine.

Are the hypothesized mechanisms sufficient to understand age group differences in
nicotine? The proposed framework provides a hypothesis regarding age group differences in
nicotine withdrawal. This mechanism involves dopamine transmission in the mesolimbic
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pathway and its regulation via excitatory and inhibitory mechanisms in the cell body region of
this pathway. This hypothesis is based on existing work that emphasizes the importance of the
mesolimbic pathway and it builds upon this literature by suggesting that amino acid systems in
the VTA may contribute to age group differences in nicotine withdrawal.
Although this framework focuses specifically on one neural system, it is recognized that
the proposed mechanisms are not likely sufficient to explain the complex mechanisms that
modulate age group differences in the behavioral effects of nicotine and withdrawal from this
drug. For example, emerging data suggests that stress systems play an important role in
mediating nicotine dependence (see Koob and Kreek, 2007). Several studies have shown that
adolescent animals display lower anxiety-like responses to nicotine and withdrawal from this
drug, suggesting that differences in stress responses may modulate age group differences in
nicotine. Other work has demonstrated that opioid receptor antagonists precipitate withdrawal
signs (Biala et al., 2005; Malin et al., 1993) and induce CPA in nicotine-treated adult rats (Ise et
al., 2000; Watkins et al., 2000). In the same regard, unpublished studies in our laboratory have
shown that administration of a kappa-opioid receptor agonist triggers nicotine withdrawal in
adult but not adolescent animals. These findings suggest that age group differences in opioid
systems may also contribute to age group differences in nicotine withdrawal. Further, it is
recognized that other dopamine pathways in the brain contribute to withdrawal states. For
example, a microdialysis study examining the neurochemical effects of mesocortical dopamine
during morphine withdrawal revealed that noradrenaline modulated an increase in dopamine
levels of the prefrontal cortex (Devoto et al., 2002). These findings suggest that not all dopamine
pathways of the brain are regulated in a manner to produce deficits in dopamine during
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withdrawal. Thus, more studies are needed to unveil the complex milieu of neural systems that
modulate enhanced vulnerability to tobacco abuse during adolescence.

IV. Clinical Relevance

There are several clinical implications of the proposed hypothesis regarding the
rewarding effects of nicotine. First, nicotine produces strong rewarding effects that drive
tobacco use during adolescence. Also, it is likely that tobacco use enhances the positive
effects of other substances, such as alcohol that is commonly abused in adolescents (Schmid
et al., 2007). Enhanced positive effects of nicotine may also facilitate affective states
produced by social interaction and risk-taking behavior that elicit positive affective states in
adolescents. Thus, the most effective avenue for reducing smoking behavior may involve
avoidance or preventative strategies that minimize tobacco use during adolescence.
There are also several clinical implications of the proposed hypothesis regarding
nicotine withdrawal. First, the current diagnostic criteria for nicotine dependence are steeped
in terms that are used to diagnose negative affective states during nicotine withdrawal in
adults that are long-term smokers. However, these diagnostic criteria may need to be
reconsidered for adolescent tobacco users that experience less nicotine withdrawal compared
to adults. Second, adolescents may be less likely to consider quitting because they are less
aware of their dependence upon nicotine due to a lack of withdrawal symptoms. However, it
should be noted that adolescents may also be less likely to consider quitting if they
experience high levels of withdrawal that maintain continued use. Lastly, the current
treatment strategies for smoking cessation focus on alleviating withdrawal via
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pharmacological approaches or nicotine replacement therapies. However, a lack of
withdrawal during adolescence implies that these treatments may be less effective in
adolescent tobacco users. Consistent with this suggestion, clinical studies in adolescents have
found that long-term abstinence rates were not closely associated with nicotine replacement
therapies (Hanson et al., 2003: Hurt et al., 2000; Moolchan et al., 2005). Furthermore, there
is some evidence to suggest that the nicotine patch did not prevent the expression of nicotine
withdrawal symptoms in adolescent smokers (Killen et al., 2001).

V. Future Directions

The hypotheses presented in this dissertation are meant to provide a framework for
the study of the psychobiological substrates mediating adolescent tobacco use. Although the
neurochemical hypotheses focused on cross-sectional differences between adolescents and
adults, future developmental studies may examine a broader range of many ages. Moreover,
the findings here may present an inroad for determining the mechanisms that confer
enhanced vulnerability to nicotine addiction in adults that were exposed to nicotine during
adolescence.
The present studies elucidated the neurochemical effects modulating age group
differences in nicotine withdrawal. However, it is not well-understood whether similar
mechanisms mediate age group differences in the neurochemical effects produced by
nicotine administration. Age group differences might be expected since a microdialysis study
showed that NAcc dopamine levels were higher in adolescents versus adults following
nicotine (Shearman et al., 2008). Moreover, acute nicotine enhanced long term potentiation
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to a larger degree in the VTA dopamine neurons of adolescent versus adult mice (Placzek et
al., 2009). Thus, it is possible that the proposed neurochemical hypothesis that modulates age
group differences in withdrawal may be responsible for mediating age group differences in
the neurochemical effects produced by nicotine. Based on the present findings, it may be
hypothesized that enhanced glutamate and reduced GABA transmission facilitates a larger
increase in NAcc dopamine transmission of adolescent versus adult rats following nicotine.
Finally, more studies are needed to functionally validate the proposed role of VTA
amino acid mechanisms in modulating age group differences in nicotine and withdrawal from
this drug. For example, based on the present findings, one might expect that glutamate
receptor expression or binding may be lower, whereas GABA receptor activity may be higher
in the VTA of adults versus adolescents experiencing withdrawal. Reversing the inhibitory
effects with glutamate agonists or GABA antagonists may present an avenue for testing
novel therapeutics to treat withdrawal in adults. Future experiments might also elucidate the
role of nicotinic receptors in mediating age group differences in the rewarding effects of
nicotine. As an example, studies might use α7 antagonists to reduce excitatory processes (i.e.,
glutamate transmission) that are believed to facilitate the rewarding effects of nicotine, and
this would be expected to reduce tobacco use in adolescents more so than adults. Recently
approved medications have already begun to explore such possibilities with a partial agonist
of the α4β2 receptor site (i.e., varenicline) that has been reported to reduce withdrawal
symptoms and the rewarding effects of nicotine (Rollema et al., 2007). The extent to which
these medications may alter amino acid transmission in an age dependent manner to promote
long-term abstinence is a future avenue of research to be followed.
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Figure 1: Mecamylamine did not alter NAcc dopamine transmission in naive adolescent or
adult rats. Data reflect % change in extracellular levels of NAcc dopamine (± SEM) plotted
across 10-minute sample collections during baseline and following administration of saline and
then 2 doses of mecamylamine in nicotine-naïve adolescent (n=6) and adult (n=6) rats. The
arrows indicate the onset of drug administration. Mecamylamine did not produce any significant
changes in NAcc dopamine relative to baseline in either age group.
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Figure 2: Nicotine withdrawal produced a decrease in VTA glutamate transmission that was
larger in adult versus adolescent rats. Data reflect % change in extracellular levels of VTA
glutamate (± SEM) plotted across 10-minute sample collections during baseline and following
administration of saline and then 2 doses of mecamylamine to precipitate withdrawal in nicotinetreated adolescent (n=7) and adult (n=14) rats. The arrows indicate the onset of drug
administration. Mecamylamine produced a decrease in VTA glutamate relative to baseline in
adult (*p<0.05) rats that was more robust relative to adolescents (†p<0.05).
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Figure 3: Nicotine withdrawal produced an increase in VTA GABA transmission that was
larger in adult versus adolescent rats. Data reflect % change in extracellular levels of VTA
GABA (± SEM) plotted across 10-minute sample collections during baseline and following
administration of saline and then 2 doses of mecamylamine to precipitate withdrawal in nicotinetreated adolescent (n=7) and adult (n=14) rats. The arrows indicate the onset of drug
administration. Mecamylamine produced an increase in VTA GABA relative to baseline in adult
(*p<0.05) rats that was more robust relative to adolescents (†p<0.05).
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Figure 4: Nicotine-treated adults experiencing withdrawal display a stronger correlation
between VTA glutamate and NAcc dopamine versus adolescents. Data reflect % change from
baseline in VTA glutamate plotted against NAcc dopamine in nicotine-treated adolescent (n=7)
and adult (n=7) rats. Each point reflects an average value across all rats for dialysate fractions
that were collected before (top panel) and after (bottom panel) mecamylamine administration.
Thus, the data points per age group reflect an average of the 12 points collected before
mecamylamine (i.e., baseline and saline) and 12 points after the 2 doses of mecamylamine.
Dopamine and glutamate were positively correlated in adults (R2=0.82; p≤0.05) following
mecamylamine administration, whereas adolescents did not display a significant correlation
(R2=0.30). The correlation was stronger in adults as compared to adolescents (p≤0.05).
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Figure 5: Nicotine-treated adults experiencing withdrawal display a stronger correlation
between VTA GABA and NAcc dopamine versus adolescents. Data reflect % change from
baseline in VTA GABA plotted against NAcc dopamine in nicotine-treated adolescent (n=7) and
adult (n=7) rats. Each point reflects an average value across all rats for dialysate fractions that
were collected before (top panel) and after (bottom panel) mecamylamine administration. Thus,
the data points per age group reflect averages of the 12 points collected before mecamylamine
(i.e., baseline and saline) and 12 points after the 2 doses of mecamylamine. Dopamine and
GABA were negatively correlated in adults (R2=0.42; p≤0.05) following mecamylamine
administration, whereas adolescents did not display a significant correlation between these
measures (R2=0.14). The correlation was stronger in adults as compared to adolescents (p≤0.05).
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